Maryland Attorney General (“AG”) Brian Frosh is not going down without a fight in his bid to defend a Maryland law prohibiting “price gouging” by generic pharmaceutical manufacturers. H.B. 631, 437th Gen. Assemb., Reg. Sess. (Md. 2017) (hereinafter, “HB 631”), was passed by the Maryland General Assembly on April 20, 2017 and was set to take effect on October 1, 2017, but for the lawsuit filed by the generic drugs trade association, Association for Accessible Medicines (“AAM”).
Baltimore Jewish Times Endorses Brian Frosh for Re-election
As attorney general, Frosh has been a faithful representative of the people’s interests, defending our rights and focusing upon the interests of citizens in need. He has also been a leader in a [...]
Washington Jewish Week Endorses Brian Frosh for Re-election
As attorney general, Frosh has been a faithful representative of the people’s interests, defending our rights and focusing upon the interests of citizens in need. He has also been a leader in a [...]
FDA Law Blog: Maryland AG Seeks SCOTUS Review of Generics Price-Gouging Prohibition Struck Down by Fourth Circuit
Maryland Attorney General (“AG”) Brian Frosh is not going down without a fight in his bid to defend a Maryland law prohibiting “price gouging” by generic pharmaceutical manufacturers. H.B. 631, 437th Gen. Assemb., [...]